A detailed history of Great West Life Assurance CO transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 26,776 shares of KRYS stock, worth $4.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
26,776
Previous 27,373 2.18%
Holding current value
$4.3 Million
Previous $5.03 Million 3.2%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$174.7 - $213.66 $104,295 - $127,555
-597 Reduced 2.18%
26,776 $4.87 Million
Q2 2024

Aug 12, 2024

BUY
$153.12 - $183.64 $3.71 Million - $4.45 Million
24,245 Added 775.1%
27,373 $5.03 Million
Q1 2024

May 13, 2024

BUY
$108.01 - $179.35 $150,889 - $250,551
1,397 Added 80.7%
3,128 $557,000
Q3 2023

Nov 14, 2023

BUY
$108.51 - $130.22 $112,850 - $135,428
1,040 Added 150.51%
1,731 $201,000
Q2 2023

Aug 10, 2023

SELL
$78.48 - $130.32 $4,316 - $7,167
-55 Reduced 7.37%
691 $82,000
Q1 2023

May 12, 2023

SELL
$72.39 - $84.27 $19,328 - $22,500
-267 Reduced 26.36%
746 $60,000
Q2 2022

Aug 12, 2022

BUY
$48.93 - $73.47 $49,566 - $74,425
1,013 New
1,013 $67,000
Q2 2022

Aug 09, 2022

SELL
$48.93 - $73.47 $49,566 - $74,425
-1,013 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$51.99 - $72.11 $17,988 - $24,950
346 Added 51.87%
1,013 $72,000
Q2 2021

Aug 11, 2021

SELL
$62.14 - $81.82 $21,003 - $27,655
-338 Reduced 33.63%
667 $45,000
Q1 2021

May 17, 2021

BUY
$59.42 - $85.46 $23,470 - $33,756
395 Added 64.75%
1,005 $77,000
Q3 2019

Oct 25, 2019

SELL
$34.72 - $51.3 $42,011 - $62,073
-1,210 Reduced 66.48%
610 $21,000
Q2 2019

Jul 31, 2019

BUY
$27.2 - $41.2 $49,504 - $74,984
1,820 New
1,820 $0

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.12B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.